Merck Due to Impose 340B Pricing Policy Changes Tomorrow

Drug manufacturer Merck is scheduled tomorrow to impose restrictions on 340B discounts when entities use contract pharmacies to dispense drugs to patients.

340B hospitals are bracing for a blow tomorrow when drug manufacturer Merck imposes restrictions on 340B discounts when hospitals use contract pharmacies to dispense drugs to patients.

Merck’s 340B contract pharmacy limitations will come on the heels of

Read More »

HRSA Veteran Herzog to Oversee 340B Program as Agency Begins Search for New OPA Director

Michelle Herzog, the new acting director of HRSA's 340B drug pricing program, speaks at the 2015 340B Coalition summer conference.

Michelle Herzog, long-time second-in-command at the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA), has taken charge as OPA director on an acting basis.

A HRSA spokesperson confirmed yesterday morning that Herzog will oversee OPA

Read More »

Bulldozing Care Barriers: How Hospitals Are Expediting Population Health Efforts Via the Pharmacy

SPONSORED CONTENT

Barriers to medication access often prevent patients with diabetes, asthma and other common chronic conditions from adhering to their therapy regimens. The result: patient outcomes suffer, and health systems struggle to achieve their population health goals.  

How can integrated pharmacy services play a key role in tackling these barriers and improving clinical results?

Join Southern Ohio Medical Center and 340B Report

Read More »

Congress Tweaks its Projection of Drug Pricing Bills’ Impact on Rx Drug Pipeline

Passing a federal law to stem rising drug prices would have a modest effect on the U.S. prescription drug pipeline, a new CBO analysis finds.

Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer

Read More »

Breaking News

News Alert: Becerra Signs off on HRSA Reorganization that Elevates 340B Program’s Status

HHS Secretary Xavier Becerra has signed off on a reorganization of HRSA that elevates decision making about the 340B program closer to the top of the department.

The 340B drug pricing program has a new, higher profile home within the U.S. Health Resources and Services Administration (HRSA), and likely is getting a new director due to its current director’s promotion.

U.S. Health and Human Services

Read More »

Health Centers Plan to Resubmit 340B Dispute Resolution Petitions

The National Association of Community Health Centers says it intends to resubmit 340B ADR claims against three drug companies. An injunction against ADR proceedings involving one of the companies has kept proceedings against the other two from moving ahead, the federal government said.

The U.S. Health Resources and Service Administration (HRSA) early this month invited community health centers to “resubmit a new” 340B administrative dispute resolution (ADR) petition against drug companies that deny or restrict 340B drug discounts when contract pharmacies

Read More »

As Frustration Mounts Over 340B Contract Pharmacy Impasse, Arguments in Highly Anticipated AstraZeneca Lawsuit Postponed to Mid-October

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s closely watched 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18.

Oral arguments previously scheduled for Sept. 14 in drugmaker AstraZeneca’s 340B contract pharmacy lawsuit against HHS and HRSA have been rescheduled for Oct. 18. The U.S. District Court for the District of Delaware announced the new date for

Read More »

Hospital Groups Back Feds in United Therapeutics 340B Contract Pharmacy Case

United Therapeutics’ denials of and restrictions on 340B pricing involving contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge.

Drug manufacturer United Therapeutics’ (UT) denials of and restrictions on 340B drug discounts when covered entities use contract pharmacies are illegal and jeopardize patient care, six hospital groups have told a federal district judge in Washington, D.C.

The

Read More »

House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to

Read More »

As Biden and House Dems Prepare to Unveil Drug Pricing Plans, 340B Providers Fret Over About Lost Savings

HHS Secretary Xavier Becerra's plan to fight excessive drug prices will be published publicly in the coming weeks, a White House official said yesterday.

As President Biden and House Democrats prepare to unveil their drug pricing game plans, 340B stakeholders eagerly await word on key provisions that could either be helpful or result in significant lost revenue.  While the proposals are going

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors